In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 4.81 below Revolution Medicines Inc average.

Within Biotechnology & Pharmaceuticals industry 65 other companies have achieved higher Quick Ratio than Revolution Medicines Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 589 to 759.

Explain Quick Ratio?
How much Cash & cash equivalents RVMD�s has?
What are RVMD�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RVMD Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	128.99 %	135.42 %	660.27 %	630.14 %	1254.91 %
Y / Y Cash & cash equivalent Change	89.04 %	84.26 %	-9.25 %	-11.52 %	24.66 %
Quick Ratio MRQ	4.81	5.54	5.28	5.1	5.83
RVMD's Total Ranking	# 759	# 589	# 137	# 491	#
Seq. Current Liabilities Change	6.78 %	96.74 %	-9.11 %	19.93 %	9.78 %
Seq. Cash & cash equivalent Change	-7.28 %	106.38 %	-5.81 %	4.88 %	-9.62 %

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 66
Healthcare Sector	# 284
Overall Market	# 759

Quick Ratio Statistics
High	Average	Low
70.03	24.59	5.1
(Sep 30 2020)		(Dec 31 2025)

Financial Statements
Revolution Medicines Inc 's Current Liabilities	$ 759 Millions	Visit RVMD's Balance sheet
Revolution Medicines Inc 's Cash & cash equivalent	$ 3,651 Millions	Visit RVMD's Balance sheet
Source of RVMD's Sales		Visit RVMD's Sales by Geography

Cumulative Revolution Medicines Inc 's Quick Ratio

RVMD's Quick Ratio for the trailling 12 Months

RVMD Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	203.07 %	320.45 %	793.83 %	666.89 %	396.91 %
Y / Y Cash & cash equivalent TTM Growth	36.2 %	21.35 %	6.24 %	14.92 %	26.34 %
Quick Ratio TTM	5.17	5.44	5.75	7.6	11.51
Total Ranking TTM	# 3901	# 2835	# 2249	# 1799	#
Seq. Current Liabilities TTM Growth	23.74 %	29.37 %	29.1 %	46.65 %	71.67 %
Seq. Cash & cash equivalent TTM Growth	17.54 %	22.5 %	-2.37 %	-3.12 %	4.73 %

Quick ratio ranking by company, industry and sector >> Back to RVMD Financial Strength Comparisons >> Go to Compare RVMD Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2026 to $758.77 millions, cumulative Quick Ratio decreased to 5.17 above the RVMD average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 141 other companies have achieved higher Quick Ratio than Revolution Medicines Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2835 to 3901.

Explain Quick Ratio?
How much Cash & cash equivalents RVMD�s has?
What are RVMD�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 142
Healthcare Sector	# 887
Within the Market	# 3901

trailing twelve months Quick Ratio Statistics
High	Average	Low
5.14	2.86	1.09
(Dec 31 2023)		(Mar 31 2026)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Tectonic Therapeutic Inc	13.05	$ 234.666 Millions	$ 17.986 Millions
Beam Therapeutics Inc	12.72	$ 1,043.873 Millions	$ 82.076 Millions
X4 Pharmaceuticals Inc	12.53	$ 187.701 Millions	$ 14.984 Millions
Odyssey Therapeutics, Inc.	12.49	$ 326.001 Millions	$ 26.101 Millions
Solid Biosciences Inc	11.46	$ 348.928 Millions	$ 30.454 Millions
Zura Bio Limited	9.22	$ 187.652 Millions	$ 20.349 Millions
Protara Therapeutics Inc	8.83	$ 127.050 Millions	$ 14.391 Millions
Repligen Corp	6.87	$ 862.979 Millions	$ 125.686 Millions
Krystal Biotech Inc	6.45	$ 916.484 Millions	$ 142.144 Millions
Voyager Therapeutics Inc	6.35	$ 106.806 Millions	$ 16.813 Millions
Cabaletta Bio Inc	6.33	$ 299.383 Millions	$ 47.332 Millions
Cognition Therapeutics inc	6.00	$ 30.758 Millions	$ 5.128 Millions
Replimune Group Inc	5.57	$ 307.833 Millions	$ 55.271 Millions
Denali Therapeutics Inc	5.42	$ 516.196 Millions	$ 95.258 Millions
In8bio Inc	5.32	$ 13.973 Millions	$ 2.628 Millions
Revolution Medicines Inc	4.81	$ 3,651.385 Millions	$ 758.773 Millions
Caribou Biosciences Inc	4.71	$ 94.881 Millions	$ 20.144 Millions
Recursion Pharmaceuticals Inc	4.47	$ 549.853 Millions	$ 122.918 Millions
Fate Therapeutics Inc	4.26	$ 139.132 Millions	$ 32.691 Millions
Kymera Therapeutics Inc	4.16	$ 373.374 Millions	$ 89.723 Millions
Monte Rosa Therapeutics Inc	4.16	$ 577.726 Millions	$ 139.022 Millions
Vir Biotechnology Inc	4.08	$ 454.635 Millions	$ 111.332 Millions
Moderna Inc	3.93	$ 7,976.000 Millions	$ 2,028.000 Millions
Immunocore Holdings Plc	3.93	$ 901.298 Millions	$ 229.619 Millions
Alector Inc	3.92	$ 138.697 Millions	$ 35.415 Millions
Dbv Technologies S a	3.89	$ 165.700 Millions	$ 42.600 Millions
Regenxbio Inc	3.71	$ 250.976 Millions	$ 67.684 Millions
Tenaya Therapeutics Inc	3.55	$ 66.797 Millions	$ 18.804 Millions
Intensity Therapeutics Inc	3.29	$ 8.494 Millions	$ 2.582 Millions
Adaptive Biotechnologies Corporation	3.02	$ 298.954 Millions	$ 98.967 Millions

Date modified: 2026-11-06T13:01:25+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.